CVS Homeopathic Childrens’ Remedies Recalled Over Belladonna Poisoning Risk

Several homeopathic kid’s teething and ear relief products sold exclusively at CVS have been recalled, due to concerns that they may contain varying amounts of belladonna, which may be harmful to children. 

The Raritan homeopathic products recall was announced by the FDA on November 24, impacting children’s teething and earache products sold at CVS stores nationwide. The products affected include CVS Homeopathic Infants’ Teething Tablets, Kids Relief Homeopathic Ear Relief Oral Liquid, and CVS Homeopathic Kids’ Ear Relief Liquid.

The recall came after the FDA tested some of the products and found varying levels of belladonna, which differ from the amounts declared on the product labels. Because the amount of belladonna in the products varies, the company decided to issue the recall “out of an abundance of caution.”

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Belladonna is a plant that is often used for medicinal products, especially homeopathic products. However, in large doses it can be toxic to humans. The varying levels of belladonna detected in the CVS homeopathic products could put children at risk, especially if they contain more than the amount stated on the labels.

The recalled homeopathic products were distributed nationally in CVS stores, including:

  • Kids Relief Homeopathic Ear Relief Oral Liquid 0.85 fl. oz., UPC 778159090639, lot35254.
  • CVS Homeopathic Kids’ Ear Relief Liquid 0.85 fl. oz., UPC 050428441633, lot33149.
  • CVS Homeopathic Infants’ Teething Tablet 135 tablet package, UPC 050428424162, lots 41116 and 43436. CVS had already removed this item from store shelves as of September 30, 2016.

Consumers are advised to stop using the affected products immediately and contact Raritan Pharmaceuticals by phone at 1-866-467-2748. If a child experiences any problems related to taking the product they should visit their doctor immediately.

Adverse events linked to the use of the recalled products should also be reported to the FDA MedWatch Adverse Event program online or by calling 800-FDA-0178.

Written by: Martha Garcia

Health & Medical Research Writer

Martha Garcia is a health and medical research writer at AboutLawsuits.com with over 15 years of experience covering peer-reviewed studies and emerging public health risks. She previously led content strategy at The Blogsmith and contributes original reporting on drug safety, medical research, and health trends impacting consumers.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A federal judge has set key scheduling deadlines for the four first bellwether trials over claims that BioZorb breast markers are defectively designed.
Parties in federal Depo-Provera meningioma lawsuits seek closer coordination with Delaware and New York state courts, proposing a synchronization of general causation schedules.
As sports-betting apps like DraftKings and FanDuel grow in popularity, treatment providers nationwide are reporting a surge in young adults seeking help for gambling addiction fueled by targeted algorithms, brain chemistry and aggressive marketing.